EGFR and non-small cell lung carcinoma: In NSCLC, where EGFR overexpression is present in about 50% of patients and has a significant negative prognostic value, while mutations in the TKD which can be targeted with TKIs are present in ~10% of cases [229], the quest to use sEV EGFR as a biomarker has been conducted mainly using antibody array techniques.